{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:38:31Z","timestamp":1771947511561,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2013R1A1A2008838"],"award-info":[{"award-number":["NRF-2013R1A1A2008838"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1A2B4011758"],"award-info":[{"award-number":["NRF-2016R1A2B4011758"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Angelica gigas<\/jats:italic> Nakai (AGN) is an oriental traditional medicine to treat anemia, dysmenorrhea, and migraine. However, its anti-lymphoma effect is yet to be tested. Here, we demonstrated that AGN and its major component decursin target <jats:italic>Myc<\/jats:italic> to suppress lymphomagenesis <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. AGN inhibited cell viability in multiple B lymphoma cells, while sparing normal splenocytes and bone marrow cells. Increased cleaved PARP level and caspase 3\/7 activity and the repression of survival-promoting AKT\/mTOR and MAPK pathways downstream of BCR, were responsible for the pro-apoptotic effects of AGN. We found that <jats:italic>Myc<\/jats:italic>, a prominent downstream target of these signaling pathways, contributes to AGN-induced cell death. Moreover, co-treatment with AGN and a Myc inhibitor, JQ1 or 10058-F4 yielded synergistic cytotoxic activities against cancer cells with markedly reduced <jats:italic>Myc<\/jats:italic> expression. AGN downregulated <jats:italic>Myc<\/jats:italic> expression and suppressed tumorigenesis in E\u03bc-myc transgenic mice. The proapoptotic activities of AGN were recapitulated by decursin, indicating that the anti-tumor effect of AGN was mainly caused by decursin. These findings suggest that AGN and decursin possess potent anti-lymphoma activity, and combination therapies with AGN\/decursin and a Myc inhibitor to target Myc more efficiently could be a valuable avenue to explore in the treatment of B-cell lymphoma.<\/jats:p>","DOI":"10.1038\/s41598-018-28619-z","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T14:43:50Z","timestamp":1530888230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Eungyoung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woochul","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3542","authenticated-orcid":false,"given":"Ismayil S.","family":"Zulfugarov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanna M.","family":"Okhlopkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniil","family":"Olennikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadezhda K.","family":"Chirikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"28619_CR1","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/1097-0142(19950101)75:1+<370::AID-CNCR2820751319>3.0.CO;2-Q","volume":"75","author":"TC Greiner","year":"1995","unstructured":"Greiner, T. C., Medeiros, L. J. & Jaffe, E. S. Non-Hodgkin\u2019s lymphoma. Cancer 75, 370\u2013380 (1995).","journal-title":"Cancer"},{"key":"28619_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3324\/haematol.2009.012864","volume":"95","author":"CJ Stasik","year":"2010","unstructured":"Stasik, C. J. et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 95, 597\u2013603, https:\/\/doi.org\/10.3324\/haematol.2009.012864 (2010).","journal-title":"Haematologica"},{"key":"28619_CR3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1182\/blood-2005-02-0687","volume":"106","author":"JS Abramson","year":"2005","unstructured":"Abramson, J. S. & Shipp, M. A. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 106, 1164\u20131174, https:\/\/doi.org\/10.1182\/blood-2005-02-0687 (2005).","journal-title":"Blood"},{"key":"28619_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMra0807082","volume":"362","author":"G Lenz","year":"2010","unstructured":"Lenz, G. & Staudt, L. M. Aggressive lymphomas. N Engl J Med 362, 1417\u20131429, https:\/\/doi.org\/10.1056\/NEJMra0807082 (2010).","journal-title":"N Engl J Med"},{"key":"28619_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511, https:\/\/doi.org\/10.1038\/35000501 (2000).","journal-title":"Nature"},{"key":"28619_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li, S., Young, K. H. & Medeiros, L. J. Diffuse large B-cell lymphoma. Pathology 50, 74\u201387, https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006 (2018).","journal-title":"Pathology"},{"key":"28619_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/187152012803833071","volume":"12","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. Anti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds. Anticancer Agents Med Chem 12, 1239\u20131254 (2012).","journal-title":"Anticancer Agents Med Chem"},{"key":"28619_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang, C. V. MYC on the path to cancer. Cell 149, 22\u201335, https:\/\/doi.org\/10.1016\/j.cell.2012.03.003 (2012).","journal-title":"Cell"},{"key":"28619_CR9","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1101\/gad.1712408","volume":"22","author":"M Eilers","year":"2008","unstructured":"Eilers, M. & Eisenman, R. N. Myc\u2019s broad reach. Genes Dev 22, 2755\u20132766, https:\/\/doi.org\/10.1101\/gad.1712408 (2008).","journal-title":"Genes Dev"},{"key":"28619_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","volume":"43","author":"AL Hsieh","year":"2015","unstructured":"Hsieh, A. L., Walton, Z. E., Altman, B. J., Stine, Z. E. & Dang, C. V. MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43, 11\u201321, https:\/\/doi.org\/10.1016\/j.semcdb.2015.08.003 (2015).","journal-title":"Semin Cell Dev Biol"},{"key":"28619_CR11","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1038\/sj.onc.1202746","volume":"18","author":"CE Nesbit","year":"1999","unstructured":"Nesbit, C. E., Tersak, J. M. & Prochownik, E. V. MYC oncogenes and human neoplastic disease. Oncogene 18, 3004\u20133016, https:\/\/doi.org\/10.1038\/sj.onc.1202746 (1999).","journal-title":"Oncogene"},{"key":"28619_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bbcan.2014.08.006","volume":"1846","author":"T Sewastianik","year":"2014","unstructured":"Sewastianik, T., Prochorec-Sobieszek, M., Chapuy, B. & Juszczynski, P. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochim Biophys Acta 1846, 457\u2013467, https:\/\/doi.org\/10.1016\/j.bbcan.2014.08.006 (2014).","journal-title":"Biochim Biophys Acta"},{"key":"28619_CR13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","volume":"98","author":"A Valera","year":"2013","unstructured":"Valera, A. et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 98, 1554\u20131562, https:\/\/doi.org\/10.3324\/haematol.2013.086173 (2013).","journal-title":"Haematologica"},{"key":"28619_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/318533a0","volume":"318","author":"JM Adams","year":"1985","unstructured":"Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533\u2013538 (1985).","journal-title":"Nature"},{"key":"28619_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.167.2.353","volume":"167","author":"AW Harris","year":"1988","unstructured":"Harris, A. W. et al. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 167, 353\u2013371 (1988).","journal-title":"J Exp Med"},{"key":"28619_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(86)90361-2","volume":"47","author":"WY Langdon","year":"1986","unstructured":"Langdon, W. Y., Harris, A. W., Cory, S. & Adams, J. M. The c-myc oncogene perturbs B lymphocyte development in E-mu-myc transgenic mice. Cell 47, 11\u201318 (1986).","journal-title":"Cell"},{"key":"28619_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R Kuppers","year":"2005","unstructured":"Kuppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5, 251\u2013262, https:\/\/doi.org\/10.1038\/nrc1589 (2005).","journal-title":"Nat Rev Cancer"},{"key":"28619_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1365-2567.2012.03564.x","volume":"136","author":"B Treanor","year":"2012","unstructured":"Treanor, B. B-cell receptor: from resting state to activate. Immunology 136, 21\u201327, https:\/\/doi.org\/10.1111\/j.1365-2567.2012.03564.x (2012).","journal-title":"Immunology"},{"key":"28619_CR19","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1182\/blood-2014-04-563890","volume":"123","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. CLL and NHL: the end of chemotherapy? Blood 123, 3368\u20133370, https:\/\/doi.org\/10.1182\/blood-2014-04-563890 (2014).","journal-title":"Blood"},{"key":"28619_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/PPO.0b013e31826c5810","volume":"18","author":"MY Choi","year":"2012","unstructured":"Choi, M. Y. & Kipps, T. J. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J 18, 404\u2013410, https:\/\/doi.org\/10.1097\/PPO.0b013e31826c5810 (2012).","journal-title":"Cancer J"},{"key":"28619_CR21","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach, J. A., Johnson, A. J. & Byrd, J. C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120, 1175\u20131184, https:\/\/doi.org\/10.1182\/blood-2012-02-362624 (2012).","journal-title":"Blood"},{"key":"28619_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1053\/j.seminhematol.2015.01.007","volume":"52","author":"N Mehta-Shah","year":"2015","unstructured":"Mehta-Shah, N. & Younes, A. Novel targeted therapies in diffuse large B-cell lymphoma. Semin Hematol 52, 126\u2013137, https:\/\/doi.org\/10.1053\/j.seminhematol.2015.01.007 (2015).","journal-title":"Semin Hematol"},{"key":"28619_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nrc2663","volume":"9","author":"TG Cotter","year":"2009","unstructured":"Cotter, T. G. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9, 501\u2013507, https:\/\/doi.org\/10.1038\/nrc2663 (2009).","journal-title":"Nat Rev Cancer"},{"key":"28619_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0092-8674(00)00116-1","volume":"103","author":"RJ Davis","year":"2000","unstructured":"Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell 103, 239\u2013252 (2000).","journal-title":"Cell"},{"key":"28619_CR25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.281.5381.1317","volume":"281","author":"G Evan","year":"1998","unstructured":"Evan, G. & Littlewood, T. A matter of life and cell death. Science 281, 1317\u20131322 (1998).","journal-title":"Science"},{"key":"28619_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1535-6108(03)00216-2","volume":"4","author":"GS Martin","year":"2003","unstructured":"Martin, G. S. Cell signaling and cancer. Cancer Cell 4, 167\u2013174 (2003).","journal-title":"Cancer Cell"},{"key":"28619_CR27","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917, https:\/\/doi.org\/10.1016\/j.cell.2011.08.017 (2011).","journal-title":"Cell"},{"key":"28619_CR28","doi-asserted-by":"publisher","unstructured":"Gomez-Curet, I. et al. c-Myc inhibition negatively impacts lymphoma growth. J Pediatr Surg 41, 207\u2013211; discussion 207\u2013211, https:\/\/doi.org\/10.1016\/j.jpedsurg.2005.10.025 (2006).","DOI":"10.1016\/j.jpedsurg.2005.10.025"},{"key":"28619_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1258-9","volume":"15","author":"M Broecker-Preuss","year":"2017","unstructured":"Broecker-Preuss, M., Becher-Boveleth, N., Bockisch, A., Duhrsen, U. & Muller, S. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability. J Transl Med 15, 158, https:\/\/doi.org\/10.1186\/s12967-017-1258-9 (2017).","journal-title":"J Transl Med"},{"key":"28619_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","volume":"21","author":"SE Trabucco","year":"2015","unstructured":"Trabucco, S. E. et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 21, 113\u2013122, https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3346 (2015).","journal-title":"Clin Cancer Res"},{"key":"28619_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary, G. S. et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis 6, e1593, https:\/\/doi.org\/10.1038\/cddis.2014.525 (2015).","journal-title":"Cell Death Dis"},{"key":"28619_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep37772","volume":"6","author":"V Pillonel","year":"2016","unstructured":"Pillonel, V. et al. Histone deacetylase 1 plays a predominant pro-oncogenic role in Emu-myc driven B cell lymphoma. Sci Rep 6, 37772, https:\/\/doi.org\/10.1038\/srep37772 (2016).","journal-title":"Sci Rep"},{"key":"28619_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2010.03.012","volume":"296","author":"WJ Kim","year":"2010","unstructured":"Kim, W. J., Lee, M. Y., Kim, J. H., Suk, K. & Lee, W. H. Decursinol angelate blocks transmigration and inflammatory activation of cancer cells through inhibition of PI3K, ERK and NF-kappaB activation. Cancer Lett 296, 35\u201342, https:\/\/doi.org\/10.1016\/j.canlet.2010.03.012 (2010).","journal-title":"Cancer Lett"},{"key":"28619_CR34","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3892\/ijo.2014.2327","volume":"44","author":"JM Kim","year":"2014","unstructured":"Kim, J. M. et al. Decursin prevents TPA-induced invasion through suppression of PKCalpha\/p38\/NF-kappaB-dependent MMP-9 expression in MCF-7 human breast carcinoma cells. Int J Oncol 44, 1607\u20131613, https:\/\/doi.org\/10.3892\/ijo.2014.2327 (2014).","journal-title":"Int J Oncol"},{"key":"28619_CR35","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1124\/mol.107.040253","volume":"72","author":"GY Song","year":"2007","unstructured":"Song, G. Y. et al. Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin. Mol Pharmacol 72, 1599\u20131606, https:\/\/doi.org\/10.1124\/mol.107.040253 (2007).","journal-title":"Mol Pharmacol"},{"key":"28619_CR36","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature22353","volume":"546","author":"G Varano","year":"2017","unstructured":"Varano, G. et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3beta inhibition. Nature 546, 302\u2013306, https:\/\/doi.org\/10.1038\/nature22353 (2017).","journal-title":"Nature"},{"key":"28619_CR37","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/his.13287","volume":"71","author":"WG Wang","year":"2017","unstructured":"Wang, W. G. et al. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma. Histopathology 71, 778\u2013785, https:\/\/doi.org\/10.1111\/his.13287 (2017).","journal-title":"Histopathology"},{"key":"28619_CR38","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/onc.2015.245","volume":"35","author":"R Gopalakrishnan","year":"2016","unstructured":"Gopalakrishnan, R. et al. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35, 1797\u20131810, https:\/\/doi.org\/10.1038\/onc.2015.245 (2016).","journal-title":"Oncogene"},{"key":"28619_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ajh.10139","volume":"70","author":"B Agarwal","year":"2002","unstructured":"Agarwal, B. & Naresh, K. N. Bcl-2 family of proteins in indolent B-cell non-Hodgkin\u2019s lymphoma: study of 116 cases. Am J Hematol 70, 278\u2013282, https:\/\/doi.org\/10.1002\/ajh.10139 (2002).","journal-title":"Am J Hematol"},{"key":"28619_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.humpath.2004.04.018","volume":"35","author":"JH Cho-Vega","year":"2004","unstructured":"Cho-Vega, J. H. et al. MCL-1 expression in B-cell non-Hodgkin\u2019s lymphomas. Hum Pathol 35, 1095\u20131100 (2004).","journal-title":"Hum Pathol"},{"key":"28619_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jpba.2007.04.006","volume":"44","author":"XL Piao","year":"2007","unstructured":"Piao, X. L., Park, J. H., Cui, J., Kim, D. H. & Yoo, H. H. Development of gas chromatographic\/mass spectrometry-pattern recognition method for the quality control of Korean Angelica. J Pharm Biomed Anal 44, 1163\u20131167, https:\/\/doi.org\/10.1016\/j.jpba.2007.04.006 (2007).","journal-title":"J Pharm Biomed Anal"},{"key":"28619_CR42","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari, R. et al. Combination therapy in combating cancer. Oncotarget 8, 38022\u201338043, https:\/\/doi.org\/10.18632\/oncotarget.16723 (2017).","journal-title":"Oncotarget"},{"key":"28619_CR43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/cr.2015.127","volume":"25","author":"CG Engelke","year":"2015","unstructured":"Engelke, C. G. & Chinnaiyan, A. M. aBETting therapeutic resistance by Wnt signaling. Cell Res 25, 1187\u20131188, https:\/\/doi.org\/10.1038\/cr.2015.127 (2015).","journal-title":"Cell Res"},{"key":"28619_CR44","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538\u2013542, https:\/\/doi.org\/10.1038\/nature14888 (2015).","journal-title":"Nature"},{"key":"28619_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543\u2013547, https:\/\/doi.org\/10.1038\/nature14898 (2015).","journal-title":"Nature"},{"key":"28619_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12906-015-0589-4","volume":"15","author":"TW Oh","year":"2015","unstructured":"Oh, T. W., Park, K. H., Jung, H. W. & Park, Y. K. Neuroprotective effect of the hairy root extract of Angelica gigas NAKAI on transient focal cerebral ischemia in rats through the regulation of angiogenesis. BMC Complement Altern Med 15, 101, https:\/\/doi.org\/10.1186\/s12906-015-0589-4 (2015).","journal-title":"BMC Complement Altern Med"},{"key":"28619_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10993","volume":"7","author":"J Hyun","year":"2016","unstructured":"Hyun, J. et al. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun 7, 10993, https:\/\/doi.org\/10.1038\/ncomms10993 (2016).","journal-title":"Nat Commun"},{"key":"28619_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621\u2013681, https:\/\/doi.org\/10.1124\/pr.58.3.10 (2006).","journal-title":"Pharmacol Rev"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28619-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28619-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28619-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:19:11Z","timestamp":1671607151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28619-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28619"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28619-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"14 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10590"}}